Drug Profile

WTX 2022

Alternative Names: WTX-2022

Latest Information Update: 23 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Warewolf Therapeutics
Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Ovarian cancer; Renal cancer

Most Recent Events

18 Dec 2025 Preclinical trials in Ovarian cancer in USA (Parenteral) prior to December 2025
18 Dec 2025 Preclinical trials in Renal cancer in USA (Parenteral) prior to December 2025
18 Dec 2025 Werewolf Therapeutics announces intention to submit an Investigational New Drug application for Ovarian cancer and renal cancer by min-2027

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com